Mode
Text Size
Log in / Sign up

Trastuzumab Deruxtecan

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of Trastuzumab Deruxtecan

7 trials tracked of Trastuzumab Deruxtecan: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 338 citations.

7Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 5 Phase 1 1
  1. Phase 3 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Completed · 338 cited
  2. Phase 2 DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) Completed
  3. Phase 2 Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens Completed
  4. Phase 2 A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer Completed
  5. Phase 2 Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) Completed
  6. Phase 2 DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease Completed
Show 1 more trials
  1. Phase 1 Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.